W. Rathmell
Last active: 4/27/2021

  1. Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. Rasmussen NR, Debebe Z, Wright TM, Brooks SA, Sendor AB, Brannon AR, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Wallen EM, Simpson C, Norris JL, Janzen WP, Rathmell WK (2014) PLoS One 9(12): e116101
    › Primary publication · 25542006 (PubMed) · PMC4277431 (PubMed Central)
  2. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. Jagsi R, Spence R, Rathmell WK, Bradbury A, Peppercorn J, Grubbs S, Moy B (2014) Oncologist 19(2): 186-92
    › Primary publication · 24449096 (PubMed) · PMC3926786 (PubMed Central)
  3. Comprehensive molecular profiling of lung adenocarcinoma. Cancer Genome Atlas Research Network (2014) Nature 511(7511): 543-50
    › Primary publication · 25079552 (PubMed) · PMC4231481 (PubMed Central)
  4. Comprehensive molecular characterization of gastric adenocarcinoma. Cancer Genome Atlas Research Network (2014) Nature 513(7517): 202-9
    › Primary publication · 25079317 (PubMed) · PMC4170219 (PubMed Central)
  5. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK (2014) Eur Urol 66(1): 77-84
    › Primary publication · 24613583 (PubMed) · PMC4058355 (PubMed Central)
  6. Characterization of HPV and host genome interactions in primary head and neck cancers. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, Lee S, Hadjipanayis AG, Ivanova EV, Wilkerson MD, Protopopov A, Yang L, Seth S, Song X, Tang J, Ren X, Zhang J, Pantazi A, Santoso N, Xu AW, Mahadeshwar H, Wheeler DA, Haddad RI, Jung J, Ojesina AI, Issaeva N, Yarbrough WG, Hayes DN, Grandis JR, El-Naggar AK, Meyerson M, Park PJ, Chin L, Seidman JG, Hammerman PS, Kucherlapati R, Cancer Genome Atlas Network (2014) Proc Natl Acad Sci U S A 111(43): 15544-9
    › Primary publication · 25313082 (PubMed) · PMC4217452 (PubMed Central)
  7. The molecular biology of renal cell carcinoma. Keefe SM, Nathanson KL, Rathmell WK (2013) Semin Oncol 40(4): 421-8
    › Primary publication · 23972705 (PubMed)
  8. Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer. Rasmussen NR, Wright TM, Brooks SA, Hacker KE, Debebe Z, Sendor AB, Walker MP, Major MB, Green J, Wahl GM, Rathmell WK (2013) J Biol Chem 288(36): 26301-26310
    › Primary publication · 23893409 (PubMed) · PMC3764835 (PubMed Central)
  9. Racial difference in histologic subtype of renal cell carcinoma. Olshan AF, Kuo TM, Meyer AM, Nielsen ME, Purdue MP, Rathmell WK (2013) Cancer Med 2(5): 744-9
    › Primary publication · 24403240 (PubMed) · PMC3892806 (PubMed Central)
  10. Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response. Desimone MC, Rathmell WK, Threadgill DW (2013) J Natl Cancer Inst 105(18): 1355-64
    › Primary publication · 23990666 (PubMed) · PMC3776265 (PubMed Central)